Considerations and evidence for an ADHD outcome measure

Area of Science:

• Pediatric Medicine
• Neurodevelopmental Disorders
• Evidence-Based Practice

Background:

• The 2011 American Academy of Pediatrics guideline for attention-deficit/hyperactivity disorder (ADHD) stresses outcome monitoring.
• Clearer recommendations are needed on how to measure ADHD treatment improvement.
• Developing a reliable outcome measure for pediatric ADHD care quality is a long-term objective.

Purpose of the Study:

• To synthesize literature on the efficacy and effectiveness of guideline-recommended ADHD treatments.
• To assess the impact of these treatments on patient outcomes in children with ADHD.
• To inform the development of a pediatric ADHD outcome measure.

Main Methods:

• A systematic literature search was performed using PubMed and MeSH terms, adhering to PRISMA protocol.
• Studies published after 2002, assessing prospective ADHD improvement with recommended treatments, were included.
• The US Preventive Services Task Force (USPSTF) criteria were used to evaluate the level of evidence and study quality.

Main Results:

• The review included 35 studies, rated as USPSTF level I, II-1, or II-2, with good or fair quality.
• DSM-criteria-based rating scales were the most common tools for measuring ADHD treatment outcomes.
• All reviewed treatments demonstrated ADHD improvement, with significant symptom reduction (20%-86%) and large effect sizes (0.15-4.57).

Conclusions:

• A consistent pattern of core symptom improvement was observed in pediatric ADHD patients across various studies and treatments.
• This evidence supports the potential for core symptom improvement within one year as a criterion for an effective outcome measure.
• Further investigation is warranted to validate this timeframe as a benchmark for pediatric ADHD outcome assessment.